Business Context and Reporting Period
This Form 8-K Current Report was filed by Maravai LifeSciences Holdings, Inc. on December 3, 2024, covering events occurring on December 3 and December 4, 2024, with an effective date of December 5, 2024. The filing details a significant leadership transition on the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and executive compensation arrangements.
Material Changes
- Departure of Executive Chairman: Carl Hull notified the Board of his decision to retire as Executive Chairman and resign from the Board, effective December 5, 2024. The departure is not related to any disagreement with management or the Board.
- Appointment of New Chairman: Robert Andrew Eckert was appointed as a director and Chairman of the Board, effective December 5, 2024. He will serve as a Class I director until the 2027 annual meeting.
Compensation, Outlook, and Risks
Compensatory Arrangements for Robert Andrew Eckert
- Cash Retainer: An annual cash retainer of $175,000, commencing January 1, 2025, paid in four equal installments in arrears.
- 2024 RSU Award: An initial grant of Restricted Stock Units (RSUs) with a grant date fair value of $750,000.
- Vesting Schedule: One-third vests immediately upon grant; the remainder vests in two equal installments on the 2025 Annual Meeting Date and the one-year anniversary thereof.
- Grant Date: Expected to be granted on December 16, 2024.
- 2025 RSU Award: A subsequent grant expected on the 2025 Annual Meeting Date with a grant date fair value of $500,000.
- Vesting Schedule: One-half vests immediately upon grant; the remainder vests on the one-year anniversary of the grant date.
- Future Compensation: Commencing in 2026, Mr. Eckert will be eligible for the same annual RSU award as other non-employee directors.
- Indemnification: Mr. Eckert will enter into the Company's standard form of indemnification agreement.
Risks and Contingencies
Vesting of the Equity Awards is subject to Mr. Eckert's continued service as a Board member. A portion of each RSU award may accelerate upon a "change in control" of the Company. The filing states there are no family relationships between Mr. Eckert and other directors/officers and no known material transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact grant date and share count for the 2024 RSU award (expected December 16, 2024) based on the closing stock price on that date.
- Review the full text of the Restricted Stock Unit Agreement forms (Exhibits 10.1 and 10.2) for specific vesting conditions and change-in-control definitions.
- Confirm the date of the 2025 Annual Meeting of Shareholders to determine the specific vesting dates for the RSU awards.
- Check subsequent filings for any updates regarding Carl Hull's post-retirement status or any other Board composition changes.